AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
2
Cyber startup Oasis secures $35 million Series A extension, doubles valuation
3
"Israel definitely needs to reconsider its strategy towards China"
4
Cyber startup Island doubles valuation to $3 billion in $175 million Series D
5
De Niro to pro-Palestinian protestors: Stop talking nonsense, go home!
More news

BioProtect

3 stories about BioProtect
Itay Barnea BioProtect

Is it time to reconsider PSA tests for Prostate Cancer?

01.09.22|Itay Barnea
“The treating physician should determine what is best for the patient based on his unique age, family history, health, lifestyle, race, ethnic background, and other factors,” writes Itay Barnea, CEO of BioProtect
חולה קורונה אשפוז בית חולים רופאים ג'נבה ז'נווה שוויץ

Which Israeli cancer treatment company raised $57 million and who is making money off double chins?

22.09.20|CTech
CTech Daily Roundup: Medtronic invests $4.5 million as part of BioProtect $25 million series D
מוסף ניתוח מנתח מנתחים רופא רופאים

Medtronic invests $4.5 million as part of BioProtect $25 million series D

22.09.20|Meir Orbach
Proceeds of the round will finance the ongoing multicenter FDA clinical trial of BioProtect's lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy